- Home
- GGB vs LEGN Comparison
GGB vs LEGN Comparison
Compare GGB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- LEGN
- Stock Information
- Founded
- GGB 1901
- LEGN 2014
- Country
- GGB Brazil
- LEGN United States
- Employees
- GGB N/A
- LEGN N/A
- Industry
- GGB Steel/Iron Ore
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- GGB Industrials
- LEGN Health Care
- Exchange
- GGB Nasdaq
- LEGN Nasdaq
- Market Cap
- GGB 5.9B
- LEGN 7.0B
- IPO Year
- GGB 1999
- LEGN 2020
- Fundamental
- Price
- GGB $2.56
- LEGN $31.13
- Analyst Decision
- GGB Buy
- LEGN Strong Buy
- Analyst Count
- GGB 3
- LEGN 12
- Target Price
- GGB $5.00
- LEGN $79.00
- AVG Volume (30 Days)
- GGB 7.9M
- LEGN 1.2M
- Earning Date
- GGB 04-28-2025
- LEGN 03-11-2025
- Dividend Yield
- GGB 5.02%
- LEGN N/A
- EPS Growth
- GGB N/A
- LEGN N/A
- EPS
- GGB 0.35
- LEGN N/A
- Revenue
- GGB $10,837,144,685.00
- LEGN $627,241,000.00
- Revenue This Year
- GGB $8.01
- LEGN $66.76
- Revenue Next Year
- GGB $4.95
- LEGN $51.82
- P/E Ratio
- GGB $7.75
- LEGN N/A
- Revenue Growth
- GGB N/A
- LEGN 119.97
- 52 Week Low
- GGB $2.67
- LEGN $30.17
- 52 Week High
- GGB $4.04
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- GGB 32.08
- LEGN 36.80
- Support Level
- GGB $2.80
- LEGN $31.17
- Resistance Level
- GGB $2.96
- LEGN $34.84
- Average True Range (ATR)
- GGB 0.07
- LEGN 1.42
- MACD
- GGB -0.03
- LEGN -0.48
- Stochastic Oscillator
- GGB 3.19
- LEGN 11.16
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutor, mechanical construction bars, reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives majority of the revenue from the North America Operations segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.